Bone remodeling: an operational process ensuring survival and bone mechanical competence

Delaisse, J. M. et al. Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 141, 115628 (2020).

Maggiano, C. M., Maggiano, I. S., Tiesler, V. G., Chi-Keb, J. R. & Stout, S. D. Methods and theory in bone modeling drift: comparing spatial analyses of primary bone distributions in the human humerus. J. Anat. 228, 190–202 (2016).

Parfitt, A. M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55, 273–286 (1994).

Frost, H. M. A synchronous group of mammalian cells whose in vivo behavior can be studied. Henry Ford. Hosp. Med. Bull. 13, 161–172 (1965).

Parfitt, A. M. The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif. Tissue Int. 36, S37–S45 (1984).

Eriksen, E. F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr. Rev. 7, 379–408 (1986).

Parfitt, A. M. The quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif. Tissue Int. 28, 1–5 (1979).

Marais, A. et al. The future of quantum biology. J. R. Soc. Interface 15, 20180640 (2018).

Manolagas, S. C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115–137 (2000).

Jilka, R. L. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med. Pediatr. Oncol. 41, 182–185 (2003).

Parfitt, A. M. Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone 30, 807–809 (2002).

Metz, L. N., Martin, R. B. & Turner, A. S. Histomorphometric analysis of the effects of osteocyte density on osteonal morphology and remodeling. Bone 33, 753–759 (2003).

Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human skeleton. Bone 75, 144–150 (2015).

Marotti, G. & Palumbo, C. The mechanism of transduction of mechanical strains into biological signals at the bone cellular level. Eur. J. Histochem. 51, 15–19 (2007).

Tiede-Lewis, L. M. et al. Degeneration of the osteocyte network in the C57BL/6 mouse model of aging. Aging 9, 2190–2208 (2017).

Lecanda, F. et al. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J. Cell Biol. 151, 931–944 (2000).

Chung, D. J. et al. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J. Cell Sci. 119, 4187–4198 (2006).

Zhang, Y. et al. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. PLoS One 6, e23516 (2011).

Green, J. Role of bone in regulation of systemic acid-base balance. Miner. Electrolyte Metab. 20, 7–30 (1994).

Bushinsky, D. A., Chabala, J. M. & Levi-Setti, R. Ion microprobe analysis of mouse calvariae in vitro: evidence for a “bone membrane”. Am. J. Physiol. Endocrinol. Metab. 256, E152–E158 (1989).

Bushinsky, D. A., Gavrilov, K., Chabala, J. M., Featherstone, J. D. & Levi-Setti, R. Effect of metabolic acidosis on the potassium content of bone. J. Bone Miner. Res. 12, 1664–1671 (1997).

Rubinacci, A., Benelli, F. D., Borgo, E. & Villa, I. Bone as an ion exchange system: evidence for a pump-leak mechanism devoted to the maintenance of high bone K⁺. Am. J. Physiol. Endocrinol. Metab. 278, E15–E24 (2000).

Dedic, C. et al. Calcium fluxes at the bone/plasma interface: acute effects of parathyroid hormone (PTH) and targeted deletion of PTH/PTH-related peptide (PTHrP) receptor in the osteocytes. Bone 116, 135–143 (2018).

Rubinacci, A. et al. Bone as an ion exchange system: evidence for a link between mechanotransduction and metabolic needs. Am. J. Physiol. Endocrinol. Metab. 282, E851–E864 (2002).

Qin, L., Liu, W., Cao, H. & Xiao, G. Molecular mechanosensors in osteocytes. Bone Res. 8, 23 (2020).

McNamara, L. M., Majeska, R. J., Weinbaum, S., Friedrich, V. & Schaffler, M. B. Attachment of osteocyte cell processes to the bone matrix. Anat. Rec. 292, 355–363 (2009).

Cabahug-Zuckerman, P. et al. Potential role for a specialized β(3) integrin-based structure on osteocyte processes in bone mechanosensation. J. Orthop. Res. 36, 642–652 (2018).

Malone, A. M. D. et al. Primary cilia mediate mechanosensing in bone cells by a calcium-independent mechanism. Proc. Natl. Acad. Sci. USA. 104, 13325–13330 (2007).

Plotkin, L. I., Speacht, T. L. & Donahue, H. J. Cx43 and mechanotransduction in bone. Curr. Osteoporos. Rep. 13, 67–72 (2015).

Wang, L. et al. Mechanical sensing protein PIEZO1 regulates bone homeostasis via osteoblast-osteoclast crosstalk. Nat. Commun. 11, 282 (2020).

Lyons, J. S. et al. Microtubules tune mechanotransduction through NOX2 and TRPV4 to decrease sclerostin abundance in osteocytes. Sci. Signal. 10, eaan5748 (2017).

Morrell, A. E. et al. Mechanically induced Ca(2+) oscillations in osteocytes release extracellular vesicles and enhance bone formation. Bone Res. 6, 6 (2018).

Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).

Kamel-ElSayed, S. A., Tiede-Lewis, L. M., Lu, Y., Veno, P. A. & Dallas, S. L. Novel approaches for two and three dimensional multiplexed imaging of osteocytes. Bone 76, 129–140 (2015).

Baron, R. & Kneissel, M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179–192 (2013).

Karner, C. M. & Long, F. Wnt signaling and cellular metabolism in osteoblasts. Cell. Mol. Life Sci. 74, 1649–1657 (2017).

Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).

Hu, H. et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132, 49–60 (2005).

Song, L. et al. Loss of Wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J. Bone Miner. Res. 27, 2344–2358 (2012).

Gaur, T. et al. Canonical Wnt signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132–33140 (2005).

Sato, T. et al. A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction. Nat. Commun. 11, 3282 (2020).

Wein, M. N. et al. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J. Bone Miner. Res. 30, 400–411 (2015).

Wein, M. N. et al. SIKs control osteocyte responses to parathyroid hormone. Nat. Commun. 7, 13176 (2016).

Stegen, S. et al. Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nat. Commun. 9, 2557 (2018).

Verborgt, O., Gibson, G. J. & Schaffler, M. B. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J. Bone Miner. Res. 15, 60–67 (2000).

Boyce, B. F. & Xing, L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473, 139–146 (2008).

Holliday, L. S., Patel, S. S. & Rody, W. J. Jr. RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling. Extracell. Vesicles Circ. Nucleic Acids 2, 18–28 (2021).

Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).

Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).

Lim, J., Burclaff, J., He, G., Mills, J. C. & Long, F. Unintended targeting of Dmp1-Cre reveals a critical role for Bmpr1a signaling in the gastrointestinal mesenchyme of adult mice. Bone Res. 5, 16049 (2017).

Xiong, J. et al. Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One 10, e0138189 (2015).

Zhao, S. et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J. Bone Miner. Res. 17, 2068–2079 (2002).

Al-Dujaili, S. A. et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J. Cell. Biochem. 112, 2412–2423 (2011).

Honma, M. et al. RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J. Bone Miner. Res. 28, 1936–1949 (2013).

Honma, M., Ikebuchi, Y. & Suzuki, H. Mechanisms of RANKL delivery to the osteoclast precursor cell surface. J. Bone Miner. Metab. 39, 27–33 (2021).

Xiong, J. et al. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat. Commun. 9, 2909 (2018).

Mizuno, A. et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 20, 337–344 (2002).

Komori, T. Cell death in chondrocytes, osteoblasts, and osteocytes. Int. J. Mol. Sci. 17, 2045 (2016).

Emerton, K. B. et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 46, 577–583 (2010).

Kennedy, O. D., Laudier, D. M., Majeska, R. J., Sun, H. B. & Schaffler, M. B. Osteocyte apoptosis is required for production of osteoclastogenic signals following bone fatigue in vivo. Bone 64, 132–137 (2014).

Aguirre, J. I. et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J. Bone Miner. Res. 21, 605–615 (2006).

Kennedy, O. D. et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone 50, 1115–1122 (2012).

Kringelbach, T. M., Aslan, D., Novak, I., Schwarz, P. & Jørgensen, N. R. UTP-induced ATP release is a fine-tuned signalling pathway in osteocytes. Purinergic Signal 10, 337–347 (2014).

Cheung, W. Y. et al. Pannexin-1 and P2X7-receptor are required for apoptotic osteocytes in fatigued bone to trigger RANKL production in neighboring bystander osteocytes. J. Bone Miner. Res. 31, 890–899 (2016).

Luckprom, P., Wongkhantee, S., Yongchaitrakul, T. & Pavasant, P. Adenosine triphosphate stimulates RANKL expression through P2Y1receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells. J. Periodontal. Res. 45, 404–411 (2010).

Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282–286 (2009).

Verborgt, O., Tatton, N. A., Majeska, R. J. & Schaffler, M. B. Spatial distribution of bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? J. Bone Miner. Res. 17, 907–914 (2002).

Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).

Messmer, D. et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307–313 (2004).

Mori, T. et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int. Immunol. 23, 701–712 (2011).

Andreev, D. et al. Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin. J. Clin. Investig. 130, 4811–4830 (2020).

Glass, D. A. et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751–764 (2005).

Walsh, M. C. & Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5, 511 (2014).

Cawley, K. M. et al. Local production of osteoprotegerin by osteoblasts suppresses bone resorption. Cell Rep. 32, 108052 (2020).

Delgado-Calle, J. et al. Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor. J. Bone Miner. Res. 32, 522–535 (2017).

Ben-Awadh, A. N. et al. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology 155, 2797–2809 (2014).

Rhee, Y. et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Miner. Res. 26, 1035–1046 (2011).

Saini, V. et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J. Biol. Chem. 288, 20122–20134 (2013).

Hongo, H. et al. Osteocytic osteolysis in PTH-treated wild-type and rankl(-/-) mice examined by transmission electron microscopy, atomic force microscopy, and isotope microscopy. J. Histochem. Cytochem. 68, 651–668 (2020).

Tazawa, K. et al. Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered. J. Bone Miner. Metab. 22, 524–529 (2004).

Misof, B. M. et al. Bone matrix mineralization and osteocyte lacunae characteristics in patients with chronic kidney disease—mineral bone disorder(CKD-MBD). J. Musculoskelet. Neuronal Interact. 19, 196–206 (2019).

Gardinier, J. D., Al-Omaishi, S., Morris, M. D. & Kohn, D. H. PTH signaling mediates perilacunar remodeling during exercise. Matrix Biol. 52-54, 162–175 (2016).

Qing, H. et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J. Bone Miner. Res. 27, 1018–1029 (2012).

Misof, B. M. et al. No role of osteocytic osteolysis in the development and recovery of the bone phenotype induced by severe secondary hyperparathyroidism in vitamin D receptor deficient mice. Int. J. Mol. Sci. 21, 7989 (2020).

Davesne, D. et al. The phylogenetic origin and evolution of acellular bone in teleost fishes: insights into osteocyte function in bone metabolism. Biol. Rev. Camb. Philos. Soc. 94, 1338–1363 (2019).

Hung, J. T. et al. Assessing the ability of zebrafish scales to contribute to the short-term homeostatic regulation of [Ca2+] in the extracellular fluid during calcemic challenges. Fish. Sci. 85, 943–959 (2019).

Marenzana, M., Shipley, A. M., Squitiero, P., Kunkel, J. G. & Rubinacci, A. Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption. Bone 37, 545–554 (2005).

Farr, J. N., Kaur, J., Doolittle, M. L. & Khosla, S. Osteocyte cellular senescence. Curr. Osteoporos. Rep. 18, 559–567 (2020).

Farr, J. N. et al. Identification of senescent cells in the bone microenvironment. J. Bone Miner. Res. 31, 1920–1929 (2016).

Uda, Y. et al. Parathyroid hormone signaling in mature osteoblasts/osteocytes protects mice from age-related bone loss. Aging 13, 25607–25642 (2021).

Hayashi, M. et al. Autoregulation of osteocyte Sema3A orchestrates estrogen action and counteracts bone aging. Cell Metab. 29, 627–637.e5 (2019).

Sharma, D. et al. The effects of estrogen deficiency on cortical bone microporosity and mineralization. Bone 110, 1–10 (2018).

Jackson, E. et al. Osteocyte Wnt/β-catenin pathway activation upon mechanical loading is altered in ovariectomized mice. Bone Rep. 15, 101129 (2021).

Ma, L. et al. Connexin 43 hemichannels protect bone loss during estrogen deficiency. Bone Res. 7, 11 (2019).

Dole, N. S. et al. Osteocyte-intrinsic TGF-β signaling regulates bone quality through perilacunar/canalicular remodeling. Cell Rep. 21, 2585–2596 (2017).

Turner, A. G., Hanrath, M. A., Morris, H. A., Atkins, G. J. & Anderson, P. H. The local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation. J. Steroid Biochem. Mol. Biol. 144, 114–118 (2014).

Yashiro, M. et al. Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor. J. Pharm. Biomed. Anal. 182, 113139 (2020).

Nociti, F. H. Jr. et al. Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes. J. Dent. Res. 93, 148–154 (2014).

Rolvien, T. et al. Vitamin D regulates osteocyte survival and perilacunar remodeling in human and murine bone. Bone 103, 78–87 (2017).

Yuan, Y. et al. Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH. PLoS One 16, e0252348 (2021).

Ito, N., Findlay, D. M., Anderson, P. H., Bonewald, L. F. & Atkins, G. J. Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J. Steroid Biochem. Mol. Biol. 136, 183–186 (2013).

Takashi, Y. & Fukumoto, S. Phosphate-sensing and regulatory mechanism of FGF23 production. J. Endocrinol. Investig. 43, 877–883 (2020).

Gooi, J. H. et al. Decline in calcitonin receptor expression in osteocytes with age. J. Endocrinol. 221, 181–191 (2014).

Davey, R. A. & Findlay, D. M. Calcitonin: physiology or fantasy? J. Bone Miner. Res. 28, 973–979 (2013).

He, Z. et al. Irisin inhibits osteocyte apoptosis by activating the Erk signaling pathway in vitro and attenuates ALCT-induced osteoarthritis in mice. Bone 141, 115573 (2020).

Wood, C. L., Pajevic, P. D. & Gooi, J. H. Osteocyte secreted factors inhibit skeletal muscle differentiation. Bone Rep. 6, 74–80 (2017).

Du, J. H. et al. The function of Wnt ligands on osteocyte and bone remodeling. J. Dent. Res. 98, 930–938 (2019).

Miller, S. C., Bowman, B. M., Smith, J. M. & Jee, W. S. S. Characterization of endosteal bone-lining cells from fatty marrow bone sites in adult beagles. Anat. Rec. 198, 163–173 (1980).

Miller, S. C., de Saint-Georges, L., Bowman, B. M. & Jee, W. S. Bone lining cells: structure and function. Scanning Microsc. 3, 953–960 (1989).

Everts, V. et al. The bone lining cell: its role in cleaning howship’s lacunae and initiating bone formation. J. Bone Miner. Res. 17, 77–90 (2002).

Bloemen, V., de Vries, T. J., Schoenmaker, T. & Everts, V. Intercellular adhesion molecule-1 clusters during osteoclastogenesis. Biochem. Biophys. Res. Commun. 385, 640–645 (2009).

Talmage, R. V. Morphological and physiological considerations in a new concept of calcium transport in bone. Am. J. Anat. 129, 467–476 (1970).

Wongdee, K., Riengrojpitak, S., Krishnamra, N. & Charoenphandhu, N. Claudin expression in the bone-lining cells of female rats exposed to long-standing acidemia. Exp. Mol. Pathol. 88, 305–310 (2010).

Andersen, T. L. et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am. J. Pathol. 174, 239–247 (2009).

Fields, G. B. Interstitial collagen catabolism. J. Biol. Chem. 288, 8785–8793 (2013).

Sprangers, S. & Everts, V. Molecular pathways of cell-mediated degradation of fibrillar collagen. Matrix Biol. 75-76, 190–200 (2019).

Delaissé, J. M. et al. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 61, 504–513 (2003).

Shi, J. et al. Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev. Biol. 313, 196–209 (2008).

Parfitt, A. M. The bone remodeling compartment: a circulatory function for bone lining cells. J. Bone Miner. Res. 16, 1583–1585 (2001).

Hauge, E. M., Qvesel, D., Eriksen, E. F., Mosekilde, L. & Melsen, F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Miner. Res. 16, 1575–1582 (2001).

Kristensen, H. B., Andersen, T. L., Marcussen, N., Rolighed, L. & Delaisse, J. M. Increased presence of capillaries next to remodeling sites in adult human cancellous bone. J. Bone Miner. Res. 28, 574–585 (2013).

Díaz-Flores, L. et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909–969 (2009).

Delaisse, J. M. The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. Bonekey Rep. 3, 561 (2014).

Eghbali-Fatourechi, G. Z. et al. Circulating osteoblast-lineage cells in humans. N. Engl. J. Med. 352, 1959–1966 (2005).

Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323–328 (2014).

Ramasamy, S. K., Kusumbe, A. P., Wang, L. & Adams, R. H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 507, 376–380 (2014).

Xie, H. et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 20, 1270–1278 (2014).

Kim, B. J. et al. Osteoclast-secreted SLIT3 coordinates bone resorption and formation. J. Clin. Investig. 128, 1429–1441 (2018).

Qiu, H., Xiao, W., Yue, J. & Wang, L. Heparan sulfate modulates Slit3-induced endothelial cell migration. Methods Mol. Biol. 1229, 549–555 (2015).

Geutskens, S. B. et al. Control of human hematopoietic stem/progenitor cell migration by the extracellular matrix protein Slit3. Lab. Investig. 92, 1129–1139 (2012).

Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154–168 (2014).

Caire, R. et al. Parathyroid hormone remodels bone transitional vessels and the leptin receptor‐positive pericyte network in mice. J. Bone Miner. Res. 34, 1487–1501 (2019).

Ominsky, M. S. et al. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81, 380–391 (2015).

Matic, I. et al. Quiescent bone lining cells are a major source of osteoblasts during adulthood. Stem Cells 34, 2930–2942 (2016).

Collin-Osdoby, P. et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659–20672 (2001).

Søe, K., Delaisse, J. M. & Borggaard, X. G. Osteoclast formation at the bone marrow/bone surface interface: importance of structural elements, matrix, and intercellular communication. Semin. Cell Dev. Biol. 112, 8–15 (2020).

Ferrier, J., Xia, S. L., Lagan, E., Aubin, J. E. & Heersche, J. N. M. Displacement and translocation of osteoblast-like cells by osteoclasts. J. Bone Miner. Res. 9, 1397–1405 (1994).

Karsdal, M. A., Fjording, M. S., Foged, N. T., Delaissé, J. M. & Lochter, A. Transforming growth factor-β-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J. Biol. Chem. 276, 39350–39358 (2001).

Saltel, F. et al. Transmigration: a new property of mature multinucleated osteoclasts. J. Bone Miner. Res. 21, 1913–1923 (2006).

Perez-Amodio, S., Beertsen, W. & Everts, V. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts. J. Bone Miner. Res. 19, 1722–1731 (2004).

Kajita, M. et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893–904 (2001).

Blavier, L. & Delaisse, J. M. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci. 108, 3649–3659 (1995).

Sato, T., Foged, N. T. & Delaissé, J. M. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J. Bone Miner. Res. 13, 59–66 (1998).

Andersen, T. L. et al. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 35, 1107–1119 (2004).

Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81–92 (1999).

Sato, T. et al. Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J. Cell Sci. 110, 589–596 (1997).

Ohuchi, E. et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 272, 2446–2451 (1997).

Engsig, M. T. et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151, 879–889 (2000).

Chellaiah, M. A. & Ma, T. Membrane localization of membrane type 1 matrix metalloproteinase by CD44 regulates the activation of pro-matrix metalloproteinase 9 in osteoclasts. Biomed. Res. Int. 2013, 302392 (2013).

Zhu, L. et al. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci. Transl. Med. 12, eaaw6143 (2020).

Møller, A. M. J. et al. Aging and menopause reprogram osteoclast precursors for aggressive bone resorption. Bone Res. 8, 27 (2020).

Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).

Jobke, B., Milovanovic, P., Amling, M. & Busse, B. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59, 37–43 (2014).

Takagi, Y. et al. Effect of nitrogen-containing bisphosphonates on osteoclasts and osteoclastogenesis: an ultrastructural study. Microscopy 70, 302–307 (2021).

Liu, H. et al. Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice. J. Mol. Histol. 46, 313–323 (2015).

Yagi, M. et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and Foreign body giant cells. J. Exp. Med. 202, 345–351 (2005).

Takito, J. & Nakamura, M. Heterogeneity and actin cytoskeleton in osteoclast and macrophage multinucleation. Int. J. Mol. Sci. 21, 6629 (2020).

Streicher, C. et al. Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci. Rep. 7, 6460 (2017).

Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292–304 (2007).

Karin, M. & Greten, F. R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749–759 (2005).

Hayden, M. S., West, A. P. & Ghosh, S. NF-κB and the immune response. Oncogene 25, 6758–6780 (2006).

Franzoso, G. et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11, 3482–3496 (1997).

Xing, L. et al. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17, 1200–1210 (2002).

Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261–1269 (2005).

Ishida, N. et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277, 41147–41156 (2002).

Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889–901 (2002).

Ruocco, M. G. et al. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677–1687 (2005).

Xiu, Y. et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J. Clin. Investig. 124, 297–310 (2014).

Luo, J. et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 22, 539–546 (2016).

Ko, Y. J. et al. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor. Clin. Transl. Med. 11, e368 (2021).

Yang, X., Pande, S., Scott, C. & Friesel, R. Macrophage colony-stimulating factor pretreatment of bone marrow progenitor cells regulates osteoclast differentiation based upon the stage of myeloid development. J. Cell. Biochem. 120, 12450–12460 (2019).

Faccio, R., Takeshita, S., Zallone, A., Ross, F. P. & Teitelbaum, S. L. c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation. J. Clin. Investig. 111, 749–758 (2003).

Scholtysek, C. et al. NR4A1 regulates motility of osteoclast precursors and serves as target for the modulation of systemic bone turnover. J. Bone Miner. Res. 33, 2035–2047 (2018).

Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758–763 (2004).

Souza, P. P. C. & Lerner, U. H. Finding a toll on the route: the fate of osteoclast progenitors after toll-like receptor activation. Front. Immunol. 10, 1663 (2019).

Yim, M. The role of toll-like receptors in osteoclastogenesis. J. Bone Metab. 27, 227–235 (2020).

Maeda, K. et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405–412 (2012).

Kobayashi, Y. et al. Wnt16 regulates osteoclast differentiation in conjunction with Wnt5a. Biochem. Biophys. Res. Commun. 463, 1278–1283 (2015).

Uehara, S. et al. Protein kinase N3 promotes bone resorption by osteoclasts in response to Wnt5a-Ror2 signaling. Sci. Signal. 10, eaan0023 (2017).

Okamoto, M. et al. Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis. Sci. Rep. 4, 4493 (2014).

Roberts, J. L. et al. Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation. Ann. N. Y. Acad. Sci. 1463, 45–59 (2020).

Akisaka, T. The ruffled border and attachment regions of the apposing membrane of resorbing osteoclasts as visualized from the cytoplasmic face of the membrane. J. Electron Microsc. 55, 53–61 (2006).

Yao, G., Feng, H., Cai, Y., Qi, W. & Kong, K. Characterization of vacuolar-ATPase and selective inhibition of vacuolar-H(+)-ATPase in osteoclasts. Biochem. Biophys. Res. Commun. 357, 821–827 (2007).

Kornak, U. et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104, 205–215 (2001).

Delaissé, J. M. et al. Proteinases in bone resorption: obvious and less obvious roles. Clin. Chim. Acta 291, 223–234 (2000).

Stenbeck, G. & Horton, M. A. Endocytic trafficking in actively resorbing osteoclasts. J. Cell Sci. 117, 827–836 (2004).

Helfrich, M. H., Nesbitt, S. A., Dorey, E. L. & Horton, M. A. Rat osteoclasts adhere to a wide range of rgd (arg-gly-asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a β3 integrin. J. Bone Miner. Res. 7, 335–343 (1992).

Faccio, R. et al. Activation of αvβ3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem. Biophys. Res. Commun. 249, 522–525 (1998).

Ross, F. P. et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J. Biol. Chem. 268, 9901–9907 (1993).

Faccio, R. et al. Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J. Cell Sci. 115, 2919–2929 (2002).

Duong, L. T., Lakkakorpi, P., Nakamura, I. & Rodan, G. A. Integrins and signaling in osteoclast function. Matrix Biol. 19, 97–105 (2000).

Xiang, B. et al. The osteoclasts attach to the bone surface where the extracellular calcium concentration decreases. Cell Biochem. Biophys. 74, 553–558 (2016).

Sims, N. A. & Martin, T. J. Osteoclasts provide coupling signals to osteoblast lineage cells through multiple mechanisms. Annu. Rev. Physiol. 82, 507–529 (2020).

Jiang, X. et al. Method development of efficient protein extraction in bone tissue for proteome analysis. J. Proteome Res. 6, 2287–2294 (2007).

Rubinacci, A. Expanding the functional spectrum of vitamin K in bone. Focus on: “vitamin K promotes mineralization, osteoblast to osteocyte transition, and an anti-catabolic phenotype by γ-carboxylation-dependent and -independent mechanisms”. Am. J. Physiol. Cell Physiol. 297, C1336–C1338 (2009).

Mizokami, A., Kawakubo-Yasukochi, T. & Hirata, M. Osteocalcin and its endocrine functions. Biochem. Pharmacol. 132, 1–8 (2017).

Lin, X., Patil, S., Gao, Y. G. & Qian, A. The bone extracellular matrix in bone formation and regeneration. Front. Pharmacol. 11, 757 (2020).

Hering, S. et al. TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples. Exp. Clin. Endocrinol. Diabetes 109, 217–226 (2001).

Oursler, M. J. Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J. Bone Miner. Res. 9, 443–452 (1994).

Tang, Y. et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757–765 (2009).

Alliston, T., Choy, L., Ducy, P., Karsenty, G. & Derynck, R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20, 2254–2272 (2001).

Breen, E. C. et al. TGF? alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype. J. Cell. Physiol. 160, 323–335 (1994).

Weivoda, M. M. et al. Osteoclast TGF-β receptor signaling induces Wnt1 secretion and couples bone resorption to bone formation. J. Bone Miner. Res. 31, 76–85 (2016).

Li, J. et al. TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nat. Commun. 10, 2795 (2019).

Kim, J. S. et al. Transforming growth factor-β1 regulates macrophage migration via RhoA. Blood 108, 1821–1829 (2006).

Takai, H. et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273, 27091–27096 (1998).

Houde, N., Chamoux, E., Bisson, M. & Roux, S. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J. Biol. Chem. 284, 23397–23404 (2009).

Ota, K. et al. TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. Endocrinology 154, 3745–3752 (2013).

Seck, T. et al. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J. Clin. Endocrinol. Metab. 83, 2331–2337 (1998).

Lean, J. M., Mackay, A. G., Chow, J. W. & Chambers, T. J. Osteocytic expression of mRNA for c-fos and IGF-I: an immediate early gene response to an osteogenic stimulus. Am. J. Physiol. Endocrinol. Metab. 270, E937–E945 (1996).

Lau, K. H. W. et al. Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. Am. J. Physiol. Endocrinol. Metab. 305, E271–E281 (2013).

Fiedler, J., Brill, C., Blum, W. F. & Brenner, R. E. IGF-I and IGF-II stimulate directed cell migration of bone-marrow-derived human mesenchymal progenitor cells. Biochem. Biophys. Res. Commun. 345, 1177–1183 (2006).

Yuan, Y. et al. Gene expression profiles and bioinformatics analysis of insulin-like growth factor-1 promotion of osteogenic differentiation. Mol. Genet. Genom. Med 7, e00921 (2019).

Xian, L. et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095–1101 (2012).

Liu, L. & Parent, C. A. Review series: TOR kinase complexes and cell migration. J. Cell Biol. 194, 815–824 (2011).

Feng, X. et al. Insulin-like growth factor 1 can promote proliferation and osteogenic differentiation of human dental pulp stem cells via mTOR pathway. Dev. Growth Differ. 56, 615–624 (2014).

Sims, N. A. & Martin, T. J. Coupling signals between the osteoclast and osteoblast: how are messages transmitted between these temporary visitors to the bone surface? Front. Endocrinol. 6, 41 (2015).

Karsdal, M. A., Neutzsky-Wulff, A. V., Dziegiel, M. H., Christiansen, C. & Henriksen, K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem. Biophys. Res. Commun. 366, 483–488 (2008).

Thudium, C. S. et al. A comparison of osteoclast-rich and osteoclast-poor osteopetrosis in adult mice sheds light on the role of the osteoclast in coupling bone resorption and bone formation. Calcif. Tissue Int. 95, 83–93 (2014).

Neutzsky-Wulff, A. V. et al. Severe developmental bone phenotype in ClC-7 deficient mice. Dev. Biol. 344, 1001–1010 (2010).

Henriksen, K. et al. Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One 6, e27482 (2011).

McClung, M. R. et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicenter, randomised, double blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 7, 899–911 (2019).

Guerrini, M. M. et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83, 64–76 (2008).

Whyte, M. P. et al. Dysosteosclerosis presents as an “osteoclast-poor” form of osteopetrosis: comprehensive investigation of a 3-year-old girl and literature review. J. Bone Miner. Res. 25, 2527–2539 (2010).

Walker, E. C. et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J. Bone Miner. Res. 23, 2025–2032 (2008).

Meshcheryakova, A., Mechtcheriakova, D. & Pietschmann, P. Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential. Expert Opin. Ther. Targets 21, 725–737 (2017).

Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764–20769 (2008).

Takeshita, S. et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J. Clin. Investig. 123, 3914–3924 (2013).

Matsuoka, K., Park, K. A., Ito, M., Ikeda, K. & Takeshita, S. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. J. Bone Miner. Res. 29, 1522–1530 (2014).

Cornish, J., Callon, K. E., Edgar, S. G. & Reid, I. R. Leukemia inhibitory factor is mitogenic to osteoblasts. Bone 21, 243–247 (1997).

Weivoda, M. M. et al. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat. Commun. 11, 87 (2020).

Kim, B. J. & Koh, J. M. Coupling factors involved in preserving bone balance. Cell. Mol. Life Sci. 76, 1243–1253 (2019).

Liu, M., Sun, Y. & Zhang, Q. Emerging role of extracellular vesicles in bone remodeling. J. Dent. Res. 97, 859–868 (2018).

Huynh, N. et al. Characterization of regulatory extracellular vesicles from osteoclasts. J. Dent. Res. 95, 673–679 (2016).

Ikebuchi, Y. et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature 561, 195–200 (2018).

Furuya, Y. et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J. Biol. Chem. 288, 5562–5571 (2013).

Portal-Núñez, S. et al. Unexpected bone formation produced by RANKL blockade. Trends Endocrinol. Metab. 28, 695–704 (2017).

Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017).

Dempster, D. W. et al. Modeling‐based bone formation in the human femoral neck in subjects treated with denosumab. J. Bone Miner. Res. 35, 1282–1288 (2020).

Wang, L., Huang, B., Chen, X. & Su, J. New insight into unexpected bone formation by denosumab. Drug Discov. Today 25, 1919–1922 (2020).

Chen, X., Zhi, X., Wang, J. & Su, J. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res 6, 34 (2018).

Amizuka, N. et al. Defective bone remodelling in osteoprotegerin-deficient mice. J. Electron Microsc. 52, 503–513 (2003).

Sone, E. et al. The induction of RANKL molecule clustering could stimulate early osteoblast differentiation. Biochem. Biophys. Res. Commun. 509, 435–440 (2019).

Pitt, J. M., Kroemer, G. & Zitvogel, L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J. Clin. Investig. 126, 1139–1143 (2016).

Ma, Q. et al. Osteoclast-derived apoptotic bodies show extended biological effects of parental cell in promoting bone defect healing. Theranostics 10, 6825–6838 (2020).

Li, D. et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016).

Ma, Q. et al. Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling. Bone Res 9, 5 (2021).

Zhao, C. et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4, 111–121 (2006).

Tazaki, Y. et al. RANKL, Ephrin-Eph and Wnt10b are key intercellular communication molecules regulating bone remodeling in autologous transplanted goldfish scales. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 225, 46–58 (2018).

Matsuo, K. & Otaki, N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adhes. Migr. 6, 148–156 (2012).

Allan, E. H. et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J. Bone Miner. Res. 23, 1170–1181 (2008).

Jacome-Galarza, C. E. et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568, 541–545 (2019).

Lassen, N. E. et al. Coupling of bone resorption and formation in real time: new knowledge gained from human haversian BMUs. J. Bone Miner. Res. 32, 1395–1405 (2017).

McDonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330–1347.e13 (2021).

Kim, S. W. et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J. Bone Miner. Res. 27, 2075–2084 (2012).

Makino, A. et al. Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: a comparison with teriparatide. Bone 142, 115651 (2021).

Zanchetta, M. B. et al. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos. Int. 29, 41–47 (2018).

Sølling, A. S., Harsløf, T. & Langdahl, B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J. Bone Miner. Res. 35, 1858–1870 (2020).

Baron, R., Vignery, A. & Van Tran, P. The significance of lacunar erosion without osteoclasts: studies on the reversal phase of the remodeling sequence. Metab. Bone Dis. Relat. Res. 2, 35–40 (1980).

Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J. Bone Miner. Res. 28, 2–17 (2013).

Yamamoto, T., Yamagata, A. & Nagai, H. A histochemical study of tartrate-resistant acid phosphatase activity in rat osteoblasts. Acta Histochem. Cytochem. 29, 221–225 (1996).

Andersen, T. L. et al. Understanding coupling between bone resorption and formation. Am. J. Pathol. 183, 1–12 (2013).

Abdelgawad, M. E. et al. Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts. Histochem. Cell Biol. 145, 603–615 (2016).

Rosenberg, N., Rosenberg, O. & Soudry, M. Osteoblasts in bone physiology-mini review. Rambam Maimonides Med. J. 3, e0013 (2012).

Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J. & Cerri, P. S. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed. Res. Int. 2015, 421746 (2015).

Yellowley, C. E., Li, Z., Zhou, Z., Jacobs, C. R. & Donahue, H. J. Functional gap junctions between osteocytic and osteoblastic cells. J. Bone Miner. Res. 15, 209–217 (2000).

Marotti, G., Ferretti, M., Palumbo, C. & Benincasa, M. Static anddynamic bone formation and the mechanism of collagen fiberorientation. Bone 25, 156 (1999).

Ferretti, M. & Palumbo, C. The osteocyte: from “prisoner” to “orchestrator”. J. Funct. Morphol. Kinesiol 6, 28 (2021).

Atkins, G. J. et al. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Miner. Res. 18, 1088–1098 (2003).

Bianco, P. & Robey, P. G. Skeletal stem cells. Development 142, 1023–1027 (2015).

Palumbo, C., Cavani, F., Sena, P., Benincasa, M. & Ferretti, M. Osteocyte apoptosis and absence of bone remodeling in human auditory ossicles and scleral ossicles of lower vertebrates: a mere coincidence or linked processes? Calcif. Tissue Int. 90, 211–218 (2012).

Bianco, P. et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med. 19, 35–42 (2013).

Sacchetti, B. et al. No identical “mesenchymal stem cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep. 6, 897–913 (2016).

Sacchetti, B. Post-natal “mesenchymal” stem cells: the assayable skeletal potency. J. Stem Cells Regen. Med. 15, 12–15 (2019).

Kuznetsov, S. A. et al. Circulating skeletal stem cells. J. Cell Biol. 153, 1133–1140 (2001).

Alm, J. J. et al. Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients. J. Orthop. Res. 28, 1634–1642 (2010).

Canalis, E. The fate of circulating osteoblasts. N. Engl. J. Med 352, 2014–2016 (2005).

Feehan, J., Nurgali, K., Apostolopoulos, V., Al Saedi, A. & Duque, G. Circulating osteogenic precursor cells: building bone from blood. EBioMedicine 39, 603–611 (2019).

Manolagas, S. C. & Parfitt, A. M. What old means to bone. Trends Endocrinol. Metab. 21, 369–374 (2010).

Weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Investig. 102, 274–282 (1998).

Moriishi, T. et al. Overexpression of BCLXL in osteoblasts inhibits osteoblast apoptosis and increases bone volume and strength. J. Bone Miner. Res. 31, 1366–1380 (2016).

Manolagas, S. C., Kousteni, S. & Jilka, R. L. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385–409 (2002).

Wang, X. et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 172, 115–125 (2006).

Liu, H. & Li, B. p53 control of bone remodeling. J. Cell. Biochem. 111, 529–534 (2010).

Bonewald, L. F. The amazing osteocyte. J. Bone Miner. Res. 26, 229–238 (2011).

Zhao, W., Byrne, M. H., Wang, Y. & Krane, S. M. Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J. Clin. Investig. 106, 941–949 (2000).

Holmbeck, K. et al. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J. Cell Sci. 118, 147–156 (2005).

Staines, K. A. et al. Hypomorphic conditional deletion of E11/podoplanin reveals a role in osteocyte dendrite elongation. J. Cell. Physiol. 232, 3006–3019 (2017).

Wang, J. S. et al. Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin. Nat. Commun. 12, 6271 (2021).

Lerebours, C. & Buenzli, P. R. Towards a cell-based mechanostat theory of bone: the need to account for osteocyte desensitisation and osteocyte replacement. J. Biomech. 49, 2600–2606 (2016).